Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GSK plc
GSK plc News
Mar 13, 2025 - accessnewswire.com
Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Mar 13, 2025 - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Mar 13, 2025 - accessnewswire.com
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
Mar 13, 2025 - accessnewswire.com
GSK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
GSK plc Quantitative Score
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
GSK plc Earnings & Revenue
GSK plc Financials
Table Compare
Compare GSK metrics with: | |||
|---|---|---|---|
Earnings & Growth | GSK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GSK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GSK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GSK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GSK plc Income
GSK plc Balance Sheet
GSK plc Cash Flow
GSK plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
GSK plc Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 1.5516 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-04-10 | 0.40065 | Quarterly |
| 2025-01-09 | 0.38905 | Quarterly |
| 2024-10-10 | 0.38567 | Quarterly |
| 2024-07-11 | 0.37619 | Quarterly |
| 2024-04-11 | 0.40606 | Quarterly |
GSK plc Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
GSK plc Executives
| Name | Role |
|---|---|
| Ms. Emma Natasha Walmsley | Chief Executive Officer & Director |
| Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director |
| Mr. Luke V. Miels | Chief Commercial Officer |
| Ms. Sally Jackson | Senior Vice President of Global Communications & Chief Executive Officer Office |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Emma Natasha Walmsley | Chief Executive Officer & Director | Female | 1969 | 5.82M |
| Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director | Female | 1962 | 5.39M |
| Mr. Luke V. Miels | Chief Commercial Officer | Male | 1975 | -- |
| Ms. Sally Jackson | Senior Vice President of Global Communications & Chief Executive Officer Office | Female | -- | |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | Male | -- |